arrow
L

Larry Rubinstein

Johns Hopkins University
H指数:70
被引数:6.7万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

A phase 1 study of orally administered 5-fluoro-2’-deoxycytidine with tetrahydrouridine in patients with refractory solid tumors

一项关于口服给予5-氟-2’-脱氧胞苷与四氢尿嘧啶联合治疗难治性实体瘤的1期研究

2025-12-220
OAAI
Establishing the content validity of patient-reported outcome measures used in neuro-oncology based on the WHO ICF framework: Part of the RANO-PRO initiative

基于WHO ICF框架建立神经肿瘤学中使用的患者报告结局指标的内容效度:RANO-PRO计划的一部分

2025-06-010
PRE
Phase 1 studies of the indenoisoquinolines LMP776 and LMP744 in patients with solid tumors and lymphomas

I期研究评估吲哚异喹啉类化合物LMP776和LMP744在实体瘤和淋巴瘤患者中的应用

2025-05-290
OAAI
Assessment of Patient-Derived Xenograft Growth and Antitumor Activity: The NCI PDXNet Consensus Recommendations
2024-04-193
OAAI
Pharmacodynamics-driven phase 2 trial of talazoparib in patients with advanced solid tumors and aberrations in genes involved in DNA damage response
2023-12-010
PRE
The NCI-MATCH trial: lessons for precision oncology
2023-06-1545
PRE
ETCTN 10388: a first in human phase I trial of triapine and lutetium Lu 177 DOTATATE in well-differentiated somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEPNETs)
2023-04-140
PRE
Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trial
2022-03-0120
OAAI
Erdafitinib in patients with tumors harboring FGFR gene mutations or fusions: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Sub-protocol K2
2021-12-012
PRE
The Molecular Analysis for Therapy Choice (NCI-MATCH) Trial: Lessons for Genomic Trial Design (vol 112, djz245, 2020)
2021-08-210
OAAI
Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q (vol 30, pg 1821, 2019)
2021-08-010
OAAI
Binimetinib in patients with tumors with NRAS mutations: NCI-MATCH ECOG-ACRIN Cancer Research Group subprotocol EAY131-Z1A
2020-08-150
PRE